T. Rowe Price Associates
KLRS

T. Rowe Price Associates’s Kalaris Therapeutics KLRS Stock Holding History

T. Rowe Price Associates’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,735
Closed -$70K – 3070
2024
Q3 		$70K Hold
3,735
– – ﹤0.01% 2885
2024
Q2 		$62K Sell
3,735
-525
-12% -$9.27K ﹤0.01% 2831
2024
Q1 		$74K Buy
4,260
+2,387
+127% +$38.9K ﹤0.01% 2827
2023
Q4 		$30K Hold
1,873
– – ﹤0.01% 2851
2023
Q3 		$93K Buy
1,873
+605
+48% +$41.2K ﹤0.01% 2684
2023
Q2 		$100K Buy
1,268
+132
+12% +$12.5K ﹤0.01% 2699
2023
Q1 		$103K Sell
1,136
-565
-33% -$72K ﹤0.01% 2683
2022
Q4 		$201K Sell
1,701
-445
-21% -$75.5K ﹤0.01% 2532
2022
Q3 		$390K Sell
2,146
-54
-2% -$8.41K ﹤0.01% 2254
2022
Q2 		$197K Buy
2,200
+1,005
+84% +$105K ﹤0.01% 2610
2022
Q1 		$185K Buy
1,195
+300
+34% +$59.8K ﹤0.01% 2732
2021
Q4 		$266K Buy
+895
New +$415K ﹤0.01% 2646

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's KLRS Position: Q4 2024 in Review

T. Rowe Price Associates sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 3,735 shares — an estimated $70K sold.

T. Rowe Price Associates first reported a position in KLRS in Q4 2021 and held it in 12 quarters. The position peaked at $390K in Q3 2022. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • T. Rowe Price Associates reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,735 Kalaris Therapeutics shares in Q4 2024, an estimated $70K.
  • T. Rowe Price Associates first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 12 quarters.
  • T. Rowe Price Associates's Kalaris Therapeutics position peaked at $390K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.